Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 19

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 19
---
1 1 Additional paid-in capital1,190,104 1,149,643 Accumulated deficit(795,761)(744,674)Accumulated other comprehensive loss(33,763)(36,261)Total shareholders’ equity360,716 368,843 Total liabilities and shareholders’ equity$1,009,506 $597,001 

The accompanying notes form an integral part of these consolidated financial statements.

F-5

Table of Contents

Immunocore Holdings Plc

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

Year Ended December 31,202420232022Revenue:Revenue from sale of therapies, net$309,989 $238,735 $140,687 Collaboration revenue213 10,693 33,674 Total revenue310,202 249,428 174,361 Cost and operating expenses:Cost of revenue from sale of therapies(2,731)(1,037)(1,089)Research and development expenses(222,151)(163,545)(101,921)Selling, general and administrative expenses(155,781)(144,495)(123,059)Loss from operations(70,461)(59,649)(51,708)Other income (expense):Interest income25,618 17,986 3,756 Interest expense(18,844)(5,154)(5,409)Foreign currency (loss) gain(3,448)(13,176)14,157 Other income (expense), net14,198 (897)(1,679)Net loss before income taxes(52,937)(60,890)(40,883)Income tax benefit (expense)1,850 5,603 (11,660)Net loss$(51,087)$(55,287)$(52,543)Other comprehensive income (loss):Exchange differences on translation of foreign operations2,498 18,412 (24,358)Total comprehensive loss(48,589)(36,875)(76,901)Basic and diluted net loss per share$(1.02)$(1.13)$(1.15)Basic and diluted weighted-average number of shares outstanding49,991,06448,888,97545,714,923

The accompanying notes form an integral part of these consolidated financial statements.

F-6

Table of Contents

Immunocore Holdings Plc

Consolid